



NDA 050629/S-033

**SUPPLEMENT APPROVAL**

Pfizer Inc.  
Attention: William Vogt  
Director, Pfizer Global Regulatory Sciences  
66 Hudson Boulevard East  
New York, NY 10001

Dear William Vogt:

Please refer to your supplemental New Drug Application (sNDA) dated and received April 28, 2023, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for DOXORUBICIN HYDROCHLORIDE injection.

We also refer to our approval letter dated May 9, 2024, which contained the following error: The Provides For statement says [REDACTED] (b) (4) instead of the correct "clear glass vials."

This replacement approval letter incorporates the correction of the error. The effective approval date will remain May 9, 2024, the date of the original approval letter.

We acknowledge receipt of your amendment dated January 12, 2024, which constituted a complete response to our August 14, 2023, action letter.

This Prior Approval supplemental new drug application provides for:

- Addition of [REDACTED] (b) (4) (FEI # [REDACTED] (b) (4)) for the manufacture of the drug product. This change is associated with addition of an alternate immediate container-closure system, i.e., clear glass vials, for packaging the drug product.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing

information) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also, within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND CONTAINER LABELS**

Submit final printed carton and container labels that are identical to enclosed carton and container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 050629/S-033.**” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Janell Artis, PharmD., Regulatory Business Process Manager at email: [Janell.Artis@fda.hhs.gov](mailto:Janell.Artis@fda.hhs.gov), or (301) 796 – 6309.

Sincerely,

*{See appended electronic signature page}*

Ramesh Raghavachari, Ph.D.  
Supervisor  
Division of Product Quality Assessment IV  
Office of Product Quality Assessment I  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling

Carton and Container Labeling



Ramesh  
Raghavachari

Digitally signed by Ramesh Raghavachari  
Date: 5/14/2024 05:07:03PM  
GUID: 502d0913000029f375128b0de8c50020